Vysis Improperly Promoting AneuVysion Assay On Website - Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Vysis, Inc.' s website improperly promotes the AneuVysion assay as a replacement for standard cytogenic tests to diagnose certain birth defects, FDA says in a Feb. 2 warning letter to the company.